Trial
NCT04149275
Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Alabama at Birmingham
Collaborators
—
Condition
Carcinosarcoma of Ovary
Intervention
Cabozantinib
Why stopped
Funding withdrawn by sponsor
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-02-21